1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Original Article
You have full text access to this OnlineOpen article
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
Article first published online: 30 DEC 2003
DOI: 10.1002/hep.510240407
Copyright © 1996 by the American Association for the Study of Liver Diseases
1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
Additional Information
How to Cite
Fromm, M. F., Busse, D., Kroemer, H. K. and Eichelbaum, M. (1996), Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology, 24: 796–801. doi: 10.1002/hep.510240407
Publication History
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Abstract
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , Differentiating mucosal and hepatic metabolism of budesonide by local pretreatment with increasing doses of ketoconazole in the proximal jejunum, European Journal of Pharmaceutical Sciences, 2012, 46, 5, 530
- 2, , , , , Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407, Xenobiotica, 2012, 1
- 3, Cytochrome P450-mediated cardiovascular drug interactions, Expert Opinion on Drug Metabolism & Toxicology, 2011, 7, 9, 1065
- 4, , , Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs, Expert Review of Clinical Pharmacology, 2011, 4, 4, 409
- 5, , In vitroandin vivosmall intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences, Drug Metabolism Reviews, 2011, 43, 4, 476
- 6, , , , , , Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactions, Biopharmaceutics & Drug Disposition, 2011, 32, 3Direct Link:
- 7, , Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro, Cancer Chemotherapy and Pharmacology, 2011, 68, 4, 1093
- 8, , , , , , , , Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study, Clinical Pharmacology & Therapeutics, 2011, 90, 2, 263
- 9, , , , , Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover, European Journal of Pharmaceutical Sciences, 2011, 43, 3, 160
- 10, , , , , , Effect of Single-Dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers, Clinical Pharmacology & Therapeutics, 2010, 88, 4, 540
- 11, , , , , Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam, European Journal of Pharmaceutical Sciences, 2010, 39, 5, 298
- 12, , , Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions, Disease-a-Month, 2010, 56, 3, 163
- 13, , Cytochrome P450-mediated metabolism in the human gut wall, Journal of Pharmacy and Pharmacology, 2009, 61, 5Direct Link:
- 14, , , , , , , Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity, Clinical Pharmacology & Therapeutics, 2009, 87, 2, 191
- 15, , , , , , , Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs, Research in Veterinary Science, 2009, 87, 3, 455
- You have free access to this content16, , , , Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption, Journal of Pharmaceutical Sciences, 2009, 98, 6Direct Link:
- 17, , , , , , , Population-Based Mechanistic Prediction of Oral Drug Absorption, The AAPS Journal, 2009, 11, 2, 225
- 18, , , Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions, American Journal of Therapeutics, 2009, 16, 2, 155
- 19, , , , , Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats, Biopharmaceutics & Drug Disposition, 2008, 29, 1Direct Link:
- 20, , , Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions, Expert Opinion on Drug Metabolism & Toxicology, 2008, 4, 7, 909
- 21, , , Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole, European Journal of Pharmaceutical Sciences, 2008, 35, 4, 264
- 22, , Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates, Journal of Pharmaceutical Sciences, 2008, 97, 5Direct Link:
- 23, , , , , , , The recovery time-course of CYP3A after induction by St John's wort administration, British Journal of Clinical Pharmacology, 2008, 65, 5Direct Link:
- 24, , , , , , , , , , Cytochrome P450 3A5 Genotype is Associated with Verapamil Response in Healthy Subjects, Clinical Pharmacology & Therapeutics, 2007, 82, 5, 579
- 25, , , , , , , , EXPRESSION OF CYP3A ISOFORMS AND P-GLYCOPROTEIN IN HUMAN STOMACH, JEJUNUM AND ILEUM, Clinical and Experimental Pharmacology and Physiology, 2007, 34, 11Direct Link:
- 26, , , , , Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam, Caffeine, and Digoxin, Clinical Pharmacology & Therapeutics, 2007, 84, 1, 52
- 27, Stereoselectivity in drug metabolism, Expert Opinion on Drug Metabolism & Toxicology, 2007, 3, 2, 149
- 28, CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications, Pharmaceutical Research, 2006, 23, 6, 1089
- 29, , Cytochrom-P450 mediierte Arzneimittelinteraktionen mit Antibiotika, Wiener Medizinische Wochenschrift, 2006, 156, 17-18, 508
- 30, Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics, Biopharmaceutics & Drug Disposition, 2006, 27, 8Direct Link:
- 31, , , , , Effect of rifampicin on the pharmacokinetics of pioglitazone, British Journal of Clinical Pharmacology, 2006, 61, 1Direct Link:
- 32, , , , , , , Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin, Pharmacogenetics and Genomics, 2006, 16, 8, 565
- 33, , , , , , , Evaluation of Human Liver Slices and Reporter Gene Assays as Systems for Predicting the Cytochrome P450 Induction Potential of Drugs in Vivo in Humans, Pharmaceutical Research, 2006, 23, 1, 56
- 34, , , In Vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance, Journal of Pharmaceutical Sciences, 2006, 95, 6Direct Link:
- 35, , , , Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes, British Journal of Clinical Pharmacology, 2005, 59, 2Direct Link:
- 36, , , , No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis, Hepatology, 2005, 41, 3Direct Link:
- 37, , , Functional interaction of intestinal CYP3A4 and P-glycoprotein, Fundamental & Clinical Pharmacology, 2004, 18, 6Direct Link:
- 38, , , , , , , Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells, European Journal of Pharmacology, 2004, 483, 1, 19
- 39, , , , Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography–tandem mass spectrometry, Journal of Chromatography B, 2004, 804, 2, 303
- 40, , , , Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers, European Journal of Pharmaceutical Sciences, 2003, 19, 1, 57
- 41, , , Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver, European Journal of Drug Metabolism and Pharmacokinetics, 2003, 28, 1, 41
- 42, , , , Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines, Journal of Pharmacy and Pharmacology, 2003, 55, 1Direct Link:
- 43, , , , , , Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency, Kidney International, 2002, 61, 4, 1495
- 44, , , Induction of hepatic and presystemic metabolism of antipyrine in the mice: Rifampicin versus rifabutin, European Journal of Drug Metabolism and Pharmacokinetics, 2001, 26, 4, 209
- 45, , INTERINDIVIDUALVARIABILITY ININHIBITION ANDINDUCTION OFCYTOCHROMEP450 ENZYMES, Annual Review of Pharmacology and Toxicology, 2001, 41, 1, 535
- 46, , Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit, Clinical Pharmacokinetics, 2001, 40, 11, 833
- 47, , , , , , Can oral midazolam predict oral cyclosporine disposition?, European Journal of Pharmaceutical Sciences, 2000, 12, 1, 51
- 48, Enzymatic Shunting: Resolving the Acetaminophen-Warfarin Controversy, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000, 20, 12Direct Link:
- 49, , Immunochemical Identification of UGT Isoforms in Human Small Bowel and in Caco-2 Cell Monolayers, Biochemical and Biophysical Research Communications, 2000, 273, 3, 1053
- 50
- 51, , , , Rapid and highly sensitive method for the determination of verapamil, [2H7]verapamil and metabolites in biological fluids by liquid chromatography–mass spectrometry, Journal of Chromatography B: Biomedical Sciences and Applications, 2000, 738, 1, 137
- 52, , , , , , , , , The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters, The American Journal of Pathology, 2000, 157, 5, 1575
- 53, , , , , , , , , , The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function, British Journal of Clinical Pharmacology, 2000, 49, S1Direct Link:
- 54
- 55, , , , Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil, British Journal of Clinical Pharmacology, 1999, 47, 5Direct Link:
- 56, Role of pharmacokinetics in the discovery and development of indinavir, Advanced Drug Delivery Reviews, 1999, 39, 1-3, 33
- 57, , , , , The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans, British Journal of Clinical Pharmacology, 1999, 48, 2Direct Link:
- 58, , , , , , , The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin, Journal of Clinical Investigation, 1999, 104, 2, 147
- 59, Clinically important pharmacokinetic drug–drug interactions: role of cytochrome P450 enzymes, Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 6Direct Link:
- 60, , , Concentrations and effects of buspirone are considerably reduced by rifampicin, British Journal of Clinical Pharmacology, 1998, 45, 4Direct Link:
- 61, , , , , , Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction, British Journal of Clinical Pharmacology, 1998, 45, 3Direct Link:
- 62, , IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A, Annual Review of Pharmacology and Toxicology, 1998, 38, 1, 389
- 63, , , , , Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin*, Clinical Pharmacology & Therapeutics, 1998, 64, 6, 648
- 64, , , The Absence of Stereoselective P-Glycoprotein-mediated Transport of R/S-Verapamil Across the Rat Jejunum, Journal of Pharmacy and Pharmacology, 1998, 50, 7Direct Link:
- 65, , , , , , The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*, Clinical Pharmacology & Therapeutics, 1998, 64, 2, 133
- 66, Assessing the Potential for Induction of Cytochrome P450 Enzymes and Predicting the In Vivo Response,Direct Link:
- 67, , Characterization of Cytochrome P450 Mechanism-Based Inhibition, Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing,Direct Link:
- 68, , Clinical Implications of CYP Induction-Mediated Drug–Drug Interactions, Encyclopedia of Drug Metabolism and Interactions,Direct Link:
- 69, , Drug Interactions with Garlic and Ginger Supplements,Direct Link:
- 70, , Drug Metabolism in Gastrointestinal Tract,Direct Link:
- 71Evaluation of Drug–Drug Interaction Risk with PBPK Models,Direct Link:
- 72, , , , , Human Biotransformation,Direct Link:
- 73, Oral Absorption: from Physiology to Regulatory, Encyclopedia of Drug Metabolism and Interactions,Direct Link:
- 74, Simulation of Population Variability in Pharmacokinetics,Direct Link: